The mutagenicity, metabolism, DNA adduction and induction of unscheduled DNA synthesis (UDS) of 1-nitropyrene and 1,8-dinitropyrene were investigated in the human hepatoma cell line HepG2. Previous results had demonstrated that 1-nitropyrene was both mutagenic at the hgprt locus and induced UDS in these cells. In the present study, we find that the dinitropyrenes, although highly mutagenic in Salmonella typhimurium, are not mutagenic and do not induce UDS in the HepG2. Although the rate of 1,8-dinitropyrene nitroreduction was less than that of 1-nitropyrene nitroreduction, this did not explain the lack of mutagenicity and UDS induction by the dinitropyrenes. Therefore, it is proposed that the arylhydroxylamine O-esterificase is not expressed in these cells. Since cytochrome P450-mediated C-oxidation is the predominant metabolic pathway in vivo, we sought to determine if an increase in the ratio of cytochrome P450-mediated C-oxidation over nitroreduction would result in increased or decreased DNA adducts in the HepG2. The administration of 2.5 pM 3-methylcholanthrene to the HepG2 increased the ratio of C-oxidation/nitroreduction from 2.8 ± 1.9 to 50.4 ± 46.1. This was accompanied by a decrease in the C8-guanyl adduct of 1-nitropyrene (via nitroreduction) from 18.7 ± 7.0 to 4.8 ± 1.7 fmoles/pg DNA, without any further increase in other 1-nitropyrene DNA adducts. These results suggest that the cytochrome P450-mediated metabolism of 1-nitropyrene to epoxides, phenols, and dihydrodiols is not an activation pathway in the HepG2 cells, and may explain the weak carcinogenicity of 1-nitropyrene in vivo, where cytochrome P450-mediated C-oxidation predominates. -Environ Health Perspect 102 (Suppl 6):195-200 (1994) 
Introduction
The method for assessing the human risk of a chemical is to use the in vivo and in vitro data on the mutagenicity and tumorigenicity of the chemical, and to determine the likelihood for human genotoxicity or adverse health effects. Risk assessment evaluations take into consideration in vitro data from both prokaryotic and eukaryotic cell studies, as well as in vivo toxicity studies from several species. It would be most advantageous to study the metabolism and genotoxicity of chemicals in vitro in human cells that metabolically resemble the cell of interest in humans. While studying the metabolism and genotoxicity of chemicals in vitro ignores the interaction of chemicals Telephone (501) 543-7000. and metabolites between cells or organs (e.g. enterohepatic circulation), it may present a simulated environment in which to study the generation of reactive metabolites within a human cell.
The human hepatoma cell holds good promise as an in vitro candidate for studies on xenobiotic metabolism. The isolation of primary human hepatocytes is restricted by a lack of availability of tissue, and poses the additional problem of interindividual variation. Several hepatoma cell lines have been isolated, with the most promising being the HepG2 cell line. This cell line was derived from a primary hepatoblastoma isolated from an 11-year-old Argentinean male (1). These cells retain many characteristic enzyme pathways of hepatocytes (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) , and have been cultured successfully for more than 100 passages.
The HepG2 has been shown by several groups to possess the enzymes necessary for the activation of many chemicals. For instance, Diamond and coworkers (16) demonstrated that when X-ray-irradiated HepG2 was cocultured for 48 (20, 21) , aflatoxin B1, (22, 23) , several N-nitroso compounds (24) , benzidine (23, 25) (21) .
The metabolism of 1-nitropyrene has been shown to involve both cytochrome P450-mediated C-oxidation (26) (27) (28) (29) (30) and nitroreduction (31) (32) (33) (34) (35) . The C-oxidation region oxides, 1-nitropyrene-4,5-oxide and 1-nitropyrene-9,10-oxide (Figure 1 , structures 1,2). The K-region oxides are mutagenic in Salmonella typhimurium either with or without exogenous activating enzymes (35, 36) . The K-region oxides can be hydrolyzed by epoxide hydrolase to the corresponding K-region trans-dihydrodiols (structures 3,4), or can rearrange to form four K-region phenols (structures 5-8). Alternatively, cytochrome P450 can catalyze the direct formation of three phenols (structures 9-11). Each of these phenols has been reported to have differing mutagenicities in S. typhimurium, presumably through nitroreduction to hydroxylamine derivatives (37, 38) . Not shown in Figure 1 are the conjugation of these phenols to sulfate and glucuronide derivatives, or the hydrolysis of the epoxides via glutathione and glutathione transferases.
In S. typhimurium, 1-nitropyrene is mutagenic through nitroreduction to the corresponding nitroso (structure 12) then the hydroxylamino (structure 13) derivative, which has been shown to form a C8-guanyl adduct (32) . This adduct also is responsible for the mutagenicity of 1- nitropyrene in CHO cells (34) , and cultured human diploid fibroblasts (39) (40) .
We demonstrated earlier that HepG2 activates 1-nitropyrene to a mutagenic metabolite (41) However, the pathways responsible for this activation were not known. Moreover, both cytochrome P450-mediated C-oxidized metabolites and nitroreduced metabolites (1-aminopyrene) were detected (41) . Therefore, we were unable to deduce the pathway or the DNA adduct responsible for the mutagenesis of 1-nitropyrene in HepG2.
The C-oxidative metabolism of 1-nitropyrene in different species is catalyzed by different cytochrome P450s [P450 2C3 in rabbit (28) ; P4503A4 in human (30) ; and P4502B1 and P4502C in rat (Howard, unpublished) ]. Additionally, the nitroreduction of 1-nitropyrene is catalyzed by several enzymes in bacteria (42, 43) , and several enzymes, including NADPHdependent cytochrome P450 reductase, DT-diaphorase, aldehyde oxidase, xanthine oxidase, and lipoyl dehydrogenase, in mammalian cells (44) (45) (46) (47) .
Therefore we sought to determine whether 1,8-dinitropyrene, like 1-nitropyrene, was mutagenic in HepG2 cells, and to describe the pathway involved in the metabolic activation of 1-nitropyrene and 1,8-dinitropyrene in HepG2.
Materials and Methods

Culture ofHepG2 Cells
HepG2 cells were obtained from L. Diamond (Wistar Institute, Philadelphia, PA), and from the American Type Culture Collection (Rockville, MD). The cells were grown essentially as described in Eddy et al. (41) at 37°C in 5% CO2 in humidified air on 100 mm tissue culture plates in Minimal Essential Medium (MEM; GIBCO) with 10% heat-inactivated (56°C, 30 min) fetal bovine serum (hi-FBS; ICN Biomedicals), and 10 units/ml penicillin and 10 g/ml streptamycin sulfate (GIBCO). The cells were subcultured (1:3) every 3 to 4 days using trypsin (GIBCO).
Mutagenesis and Unscheduled DNA Synthesis in HepG2 Cells
The mutagenesis of the chemicals by selection of mutations at the hgprt locus and the quantitation of induction of unscheduled DNA synthesis (UDS) were essentially as described in methylcholanthrene DNA adducts ( Figure  4D ). There was a lack of formation of other DNA adducts that could be attributable to 1-nitropyrene K-region epoxides. The DNA from the HepG2 treated with 1-nitropyrene contained 18.7 ± 7.0 fmoles/pg DNA of dG-C8-AP, while the cells pretreated with 3-methylcholanthrene then treated with 1-nitropyrene had 4.8 ± 1.7 fmoles dG-C8-AP per pg DNA.
These results demonstrate that when the ratio of cytochrome P450-mediated Coxidation of 1-nitropyrene is increased over the nitroreduction pathway, there is a decrease in the formation of dG-C8-AP DNA adducts, which arise from the nitroreduction pathway, and that this decrease in adducts is not associated with the formation of DNA adducts arising from cytochrome P450-mediated C-oxidation, e.g., the 4,5-epoxide DNA adduct.
Nitroreduction is not a favored pathway in vivo in tissues where cytochrome P450 concentrations are significantly higher than in HepG2 cells. Additionally, the epoxides of 1-nitropyrene are quickly hydrolyzed by epoxide hydrolase in human liver tissue (54) . These results, along with the weak tumorigenic response of rodents to 1-nitropyrene, indicate that 1-nitropyrene may not pose a significant tumorigenic risk to the human population.
